A prospective randomized, double-blind phase 2 study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: Compared with 68Ga-DOTATATE

#3333

Introduction: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 are somatostatin receptor subtype 2 specific antagonists used for PET/CT imaging.

Aim(s): The purpose of this study is to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors.

Materials and methods: A total of 40 patients with well-differentiated NETs were prospectively recruited and equally randomized into two arms: Arm A, patients would undergo a whole-body 68Ga-NODAGA-LM3 PET/CT scan on the 1st day and 68Ga-DOTATATE PET/CT scan on the 2nd day, Arm B, patients would undergo a whole-body 68Ga-DOTA-LM3 PET/CT scan on the 1st day and 68Ga-DOTATATE PET/CT scan on the 2nd day. Biodistribution in normal organs, lesion detection ability, and tumor uptake were compared between antagonists and agonist in both arms.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Zhu W, Jia R, Cheng Y, Zhao H, Bai C,

Keywords: somatostatin receptor antagonist, 68Ga-NODAGA-LM3, 68Ga-DOTA-LM3, 68Ga-DOTATATE, neuroendocrine tumor,